Sunday, March 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Dr. John Snow was the first to use mapping techniques to discover how Cholera is spread

Cholera was one of the deadliest diseases to affect Britain in the nineteenth century causing a series of pandemics in London in the 19th century.

In the nineteenth century it was believed that the disease was transmitted and spread by a ‘bad air’ or ‘bad smells’ from rotting organic waste. This thinking dominated official medical and government statements. But it was not until 1854 that the physician John Snow (1813-1858) made a major contribution to fighting cholera when he was able to demonstrate a link between cholera and the contaminated drinking water through his disease maps.

John Snow was born in York on 15 March 1813. He went to Newcastle upon Tyne at the age of 14 to work as an apprentice for the surgeon William Hardcastle. He then went on to study at the Newcastle Infirmary. During the 1831 outbreak of cholera in the North East, he attended to sufferers in the Killingworth Colliery. The excellent observations he made on the disease at this time formed the basis for his later work.

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!